Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

5.730 -0.240 (-4.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,542,553
Open 5.920
Bid (Size) 5.720 (1,000)
Ask (Size) 5.750 (100)
Prev. Close 5.970
Today's Range 5.710 - 6.060
52wk Range 2.745 - 8.440
Shares Outstanding 287,686,199
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Appoints Dr. Lynn Seely to its Board of Directors
From AbCellera Biologics Inc.
Via Business Wire

Performance

YTD
+67.1%
+67.1%
1 Month
-0.2%
-0.2%
3 Month
+43.6%
+43.6%
6 Month
+37.7%
+37.7%
1 Year
+11.3%
+11.3%

More News

Read More
News headline image
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Biologics Inc (NASDAQ:ABCL) Reports Narrower-Than-Expected Loss on Patent Settlement Windfall ↗
Via Chartmill
Topics Intellectual Property
News headline image
AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam ↗
Via MarketBeat
News headline image
AbCellera Biologics Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
AbCellera (ABCL) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Topics Intellectual Property
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at Upcoming Investor Conferences in May and June 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
CRA: Here’s the TFSA Contribution Room for 2026 and Why Now Is the Best Time to Use It ↗
Via The Motley Fool
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
AbCellera Reports Full Year 2025 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
AbCellera to Present at Upcoming Investor Conferences in March and April 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera and Bruker Reach Global Settlement of Patent Litigation
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AI Stocks Extend Selloff, Nasdaq 100 Eyes Worst Week Since April: What's Moving Markets Friday? ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
AbCellera Biologics Inc (NASDAQ:ABCL) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss ↗
Via Chartmill
News headline image
AbCellera Reports Q3 2025 Business Results
From AbCellera Biologics Inc.
Via Business Wire

Frequently Asked Questions

Is AbCellera Biologics Inc. - Common Shares publicly traded?
Yes, AbCellera Biologics Inc. - Common Shares is publicly traded.
What exchange does AbCellera Biologics Inc. - Common Shares trade on?
AbCellera Biologics Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AbCellera Biologics Inc. - Common Shares?
The ticker symbol for AbCellera Biologics Inc. - Common Shares is ABCL on the Nasdaq Stock Market
What is the current price of AbCellera Biologics Inc. - Common Shares?
The current price of AbCellera Biologics Inc. - Common Shares is 5.730
When was AbCellera Biologics Inc. - Common Shares last traded?
The last trade of AbCellera Biologics Inc. - Common Shares was at 07/22/26 04:00 PM ET
What is the market capitalization of AbCellera Biologics Inc. - Common Shares?
The market capitalization of AbCellera Biologics Inc. - Common Shares is 1.65B
How many shares of AbCellera Biologics Inc. - Common Shares are outstanding?
AbCellera Biologics Inc. - Common Shares has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.